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A B S T R A C T
Metabolic diseases such as type 2 diabetes are a major public health issue worldwide. These diseases are often
linked to a dysfunctional adipose tissue. Fat is a large, heterogenic, pleiotropic and rather complex tissue. It is
found in virtually all cavities of the human body, shows unique plasticity among tissues, and harbors many cell
types in addition to its main functional unit – the adipocyte. Adipose tissue function varies depending on the
localization of the fat depot, the cell composition of the tissue and the energy status of the organism. While the
white adipose tissue (WAT) serves as the main site for triglyceride storage and acts as an important endocrine
organ, the brown adipose tissue (BAT) is responsible for thermogenesis. Beige adipocytes can also appear in
WAT depots to sustain heat production upon certain conditions, and it is becoming clear that adipose tissue
depots can switch phenotypes depending on cell autonomous and non-autonomous stimuli. To maintain such
degree of plasticity and respond adequately to changes in the energy balance, three basic processes need to be
properly functioning in the adipose tissue: i) adipogenesis and adipocyte turnover, ii) metabolism, and iii)
signaling. Here we review the fundamental role of small non-coding RNAs (sncRNAs) in these processes, with
focus on microRNAs, and demonstrate their importance in adipose tissue function and whole body metabolic
control in mammals.
1. Metabolic diseases
Obesity statistics are alarming. According to the World Health
Organization (WHO), more than 1.9 billion adults were overweight in
2014, and more than half a billion were obese. Once an exclusive issue
of high-income countries, obesity is now prevalent in the developing
world and has been considered a global epidemic [1]. This is extremely
worrisome given that obesity represents one of the most important risk
factors for chronic diseases, including type 2 diabetes (T2D), cardio-
vascular diseases and cancer – the leading causes of mortality and
morbidity worldwide [2]. When appearing together, these diseases are
classified as a broader syndrome often referred to as the “metabolic
syndrome” [3].
The increase in the prevalence of obesity is due to many factors
including genetics, diet, sedentarism and issues concerning the psy-
chological, socioeconomic, or educational status of the individual [4].
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Simplistically, obesity appears when there is a positive energetic
balance, i.e. when energy consumption (food intake) overcomes energy
expenditure [5,6]. The definition and classification of obesity is still a
subject of debate. The WHO divides individuals into four categories
based on their body mass index (BMI, kg/m2): underweight BMI <
18.50, normal weight BMI=18.50–24.99, overweight=BMI 25.00–
29.99, and obese BMI≥30.00 [7]. This sole parameter often creates
confusion regarding the risk of metabolic diseases, since individuals
can be classified as overweight or obese but do not display increased
risk of mortality nor any metabolic alteration [8,9]. Moreover, in some
cases even a negative association between BMI and mortality - in
particular cardiovascular mortality – is found [10]. To avoid misdiag-
nosis, supporting clinical information needs to be taken into consid-
eration, such as patient's life history (e.g. addictive behavior or body
weight oscillation) and localization of excessive fat mass (e.g. upper
body or lower body) [8,11,12]. When considering the latter, obesity can
be further classified into an android syndrome (i.e. male-type or apple-
shaped), where fat is deposited preferentially in intra-abdominal
regions (i.e. visceral white adipose tissue - vWAT), and a gynoid
syndrome (i.e. female-type or pear-shaped), where fat is deposited
over the gluteofemoral region (i.e. subcutaneous white adipose tissue -
sWAT) [13,14]. The first has been more commonly linked to comor-
bidities such as hypertension, dyslipidemia, and T2D [15–17], while
the second confers a neutral or even protective effect against metabolic
diseases [17,18]. To account for these differences, parameters like
waist-to-hip ratio, magnetic resonance imaging or dual-energy X-ray
absorptiometry [19,20] have been used as bona fide predictors of
metabolic diseases and as useful parameters for researchers to under-
stand how fat accumulation determines the risk of these diseases
[12,21,22].
The pleiotropic nature of fat depots has been extensively explored
in mice. For example, transplantation of sWAT from donor mice into
the intra-abdominal region of a host mouse improves metabolism by
reducing body weight and overall fat mass, increasing insulin sensitiv-
ity and whole body glucose uptake [23], and alleviating diet-induced
glucose intolerance and inflammation [24,25]. Interestingly, these
effects are minor when sWAT is transplanted into the subcutaneous
cavity and no effect is observed when vWAT is transplanted to the
intra-abdominal area [23–25], indicating that the differences between
depots are determined by intrinsic characteristics as well as by
anatomical localization. This is particularly highlighted in patients
with lipodystrophy, where the pattern of fat accumulation differs from
normal. These patients exhibit a degree of adipose tissue atrophy
(whereas some depots can be hypertrophic), and often end up
accumulating fat in non-adipose organs such as liver, heart, and
skeletal muscle – a phenomenon that is causally linked to the metabolic
syndrome [26–28]. Lipodystrophy can be classified according to fat
loss topography (e.g. general or partial) or cause (e.g. congenital or
acquired) [29,30]. The most prevalent form of lipodystrophy is
acquired by patients with HIV undergoing antiretroviral treatment
[31,32]. For instance, the highly active antiretroviral treatment (i.e. a
combination of at least three antiretroviral drugs) inhibits mitochon-
drial DNA polymerase-γ causing mitochondrial toxicity, and the use of
protease inhibitors up-regulates genes that inhibit adipocyte differen-
tiation and down-regulates pro-adipogenic transcriptional factors such
as PPAR-γ, C/EBP-α and SREBP-1, as well as genes involved in lipid
metabolism [26,33,34]. These alterations are observed in white adipo-
cytes, mainly in the subcutaneous depot either from the upper (e.g. face
and shoulder) and/or lower body (e.g. gluteal and femoral).
Additionally, HIV patients can also exhibit increased fat accumulation
in breast, cervical, dorsocervical and visceral depots [35,36].
Importantly, these patients have a higher risk to develop insulin
resistance and cardiovascular disease, and appear to age prematurely
[37–39]. Therefore, abnormal changes in adipose tissue accumulation,
independently of fat gain or loss, impact on the risk of metabolic
diseases, a feature that highlights the importance of adipose tissue to
whole body metabolic control.
2. The etiopathogenesis of metabolic diseases
Insulin resistance is a common feature of metabolic diseases and
represents the main cause of T2D [40]. Like for obesity, the prevalence
of T2D in the world is extremely high (8.8% of the world's population)
and is rapidly growing [41]. In 2015, T2D killed approximately 5
million people [42]. The causes of T2D involve both genetic [43] and
environmental factors that progressively lead to insulin resistance,
glucose intolerance, and ultimately beta-cell failure [44,45]. Several
reports support the notion that excess lipids continuously released
from visceral fat into the portal vein in obese patients is a major trigger
of T2D [46,47]. These lipids expose the liver to incremental amounts of
free fat acids (FFAs), inducing hepatic insulin resistance and affecting
gluconeogenesis [46,48]. Interestingly, like mentioned above, despite
the association between T2D and obesity, some morbidly obese
individuals as classified by BMI are significantly more glucose tolerant
than leaner individuals [49]. Again, this apparent paradox might be
explained by changes in the pattern of fat accumulation, since
increased adipose tissue expandability and plasticity, particularly of
subcutaneous depots, is linked to metabolic health [50,51]. In essence,
the proposed model evokes that every individual has a limited capacity
for fat storage, and when this limit is reached, either by obesity or
impaired adipocyte function, excess lipids accumulate ectopically,
causing lipotoxicity, inflammation, tissue dysfunction and disease
[52–54].
At the molecular level, FFAs are usually taken up by cells and
esterified into long chain acyl CoA molecules [55]. The bulk of these
metabolites are directed to beta-oxidation, but a small portion can be
converted into two lipid intermediates: diacylglycerols and ceramides
[56]. In excess, these intermediates can activate kinases such as Jun
amino-terminal kinase (JNK), IκB kinase (IKK), and protein kinase C
(PKC) [57–60], which in turn phosphorylate the insulin receptor
substrate-1 (IRS1) in serine and inhibit insulin signaling downstream
of the insulin receptor [60–62]. Furthermore, lipids can signal through
toll-like receptors or G protein-coupled receptors to cause insulin
resistance or affect insulin secretion [63,64]. Additionally, excessive
adipocyte hypertrophy without proper neovascularization creates a
pseudohypoxic state in the adipose tissue [65,66]. Altogether, these
stimuli lead to the infiltration of immune cells into the adipose tissue
[67,68]. Within the tissue, monocytes differentiate into either anti-
inflammatory M2 or pro-inflammatory M1 macrophages depending on
the niche [69]. M1 macrophages are more commonly present in
adipose tissue under obesogenic conditions, when they are activated
by fatty acids and adipocyte-derived factors, and release a variety of
pro-inflammatory cytokines that signal locally or systemically to cause
insulin resistance through the activation of the same group of kinases
and similar mechanisms as mentioned above [70,71].
Interleukin 1 beta (IL-1β) is one such pro-inflammatory cytokine
synthesized and released from M1 macrophages in the context of
obesity [72,73]. IL-1β production and secretion is controlled by the
inflammasome and contributes directly to establishment of insulin
resistance [74–76]. Supporting this notion, Ehses et al. treated type 2
diabetic Goto-Kakizaki rats with IL-1 receptor antagonist and observed
an improvement in insulin sensitivity and glucose tolerance [77]. M1
macrophages also produce tumor necrosis factor alpha (TNF-α)
[78,79]. TNF-α acts in cells within the adipose tissue and in non-
adipose tissues to inhibit the tyrosine phosphorylation of IRS1 and
therefore its activation [80,81]. Moreover, it modifies the pattern of
adipocyte differentiation [82,83] while inducing lipolysis, which in turn
increases the levels of FFAs and creates a “pro-inflammatory vicious
cycle” [84,85]. In addition to causing lipotoxicity, as mentioned before,
FFAs stimulate the synthesis of pro-inflammatory cytokines through
the toll-like receptor-4 (TLR4) pathway [86,87]. IL-6 is also involved in
the pathophysiology of obesity, but its role is more complex. It is
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increased in adipose tissue and in circulation with obesity [88,89], and
in vitro studies using adipocytes or hepatocytes chronically exposed
with high levels of IL-6 show that this cytokine impairs insulin
signaling [90–92]. However, transient or acute increases in IL-6 levels
in healthy or type 2 diabetic patients, either by exogenous infusion or
exercise, have been associated with beneficial effects, which include
increased insulin sensitivity and improved glucose uptake [93–95].
Moreover, while brown adipose tissue (BAT) transplantation from a
wild type donor mouse to a wild type recipient mouse improves glucose
tolerance, insulin sensitivity, and decreases fat mass, when BAT
isolated from a IL-6 knockout mouse is used for the transplantation
these effects are lost [96]. Indeed, the period of exposure and the
source of IL-6 determine its effects. While an acute increase can be
beneficial, chronic exposure (as in obesity) is often deleterious [97].
Sustained cellular exposure to energetic substrates such as FFAs
and glucose, in addition to systemic inflammation, also modifies the
redox state of the cell and induces oxidative stress. During obesity,
antioxidants enzymes [e.g. superoxide dismutase (SOD) and glu-
tathione peroxidase (GPX)] cannot cope with the accumulation of
reactive oxygen species (ROS) [e.g. superoxide (O2−), hydrogen per-
oxide (H2O2), and hydroxyl radical (OH
−)] [98,99], particularly in the
mitochondria [100,101]. Furthermore, TNF-α stimulates the activity of
NADPH oxidase enzymes exacerbating the generation of superoxide
[102]. Chronic exposure to ROS alters the expression of glucose
transporters and impairs insulin-stimulated glucose uptake [103].
Interestingly, rats fed a high-fat diet are not insulin resistant when
administered with the exogenous antioxidant SS31 [104,105]. In
contrast, antioxidant administration (a combination of vitamin C and
E) blunts the induction of an endogenous antioxidant response and the
amelioration of parameters of insulin sensitivity when healthy, non-
obese people are subjected to exercise [106].
Changes in the metabolic status of the adipocyte also affect the
production and secretion of adipocyte-derived factors often named
adipokines. Many adipokines have been described, including the
cytokines mentioned above, but two adipocyte-specific molecules are
worth citing: leptin and adiponectin [107]. Leptin was the first
identified adipokine. Its coding gene (Lep or ob) was found to create
a phenotype of massive obesity and infertility when mutated in
homozygosis in mice [108]. Leptin is secreted by adipocytes in
response to a positive energy balance, and acts primarily in the brain
to inhibit food intake and promote energy expenditure [109,110].
Furthermore, leptin plays a role in immunity, energy portioning and
lipid storage, as well as bone homeostasis [111]. Adiponectin is also
expressed exclusively by adipocytes and acts as an anti-diabetic,
cardioprotective adipokine. Adiponectin levels are extremely high in
circulation (7–10 mg/L) and weight loss reduces these levels [112]. In
general, adiponectin acts to improve whole body glucose homeostasis
and lipid handling [107]. Adiponectin can also reduce inflammation
and it is thought to be beneficial against the metabolic syndrome [107].
However, under certain conditions, adiponectin can hamper osteoblast
proliferation and decrease bone mass, which can be detrimental [113].
Together, these studies evidence a complex, yet fundamental role of
fatty acids, adipokines and ROS in the etiopathogenesis of metabolic
diseases, reinforcing the notion that these molecules act to maintain
organismal homeostasis and are required for normal physiology, but
can be harmful when in excess.
3. Different types of fat
Fat is a simplistic name for a rather complex tissue that exhibits
heterogeneous morphology, contains many different cell types, shows
distinct functions, and localizes in all compartments of the body. The
characteristic unit of the adipose tissue is the adipocyte – a cell that is
specialized in storing triglycerides. In addition to adipocytes, the
adipose tissue hosts stem cells, preadipocytes, fibroblasts, endothelial
cells, macrophages, and other immune system cells [114]. The adipose
tissue has been historically classified in two sub-classes: white (WAT)
and brown (BAT). This classification is based on morphological and
molecular signatures that take into account cell structure, color,
localization, vascularization, gene expression and function [115].
Adipocytes in WAT are composed by a single large unilocular lipid
droplet in the cytoplasm and a peripheral nucleus [116]. The vascular
network of WAT is dense, providing enough substrate and oxygen
delivery and facilitating the access of hormones, adipokines and other
signaling molecules [117]. In humans, WAT depots are located in
between visceral organs (vWAT; e.g. epicardial, mesenteric, omental,
retroperitoneal, and gonadal depots), and in the subcutaneous com-
partment (sWAT; e.g. abdominal, gluteal, and femoral depots) [116].
Rodents have a similar pattern of WAT distribution with slight
differences [118]. As mentioned before, vWAT differs from sWAT in
several aspects despite being both categorized as WAT. For example, in
sWAT, lipolysis is more efficiently inhibited by insulin, while the vWAT
displays a great lipolytic response to catecholamines and lower
response to insulin [119–121]. Furthermore, vWAT produces and
releases more of the pro-inflammatory molecules that are associated
with insulin resistance and T2D [88,122,123]. It also expresses
angiotensinogen – a precursor of angiotensin II - providing a mechan-
istic link to cardiovascular disease [124]. On the other hand, sWAT
shows a more plastic, intermediate phenotype that confers it vWAT-
like or BAT-like characteristics depending on the condition [125,126].
This aspect will be discussed later in this section.
Undoubtedly, one of the main functions of WAT is to store energy
and mobilize nutrients in periods of negative energy balance. In
addition, WAT has many other important roles: i) protecting organs
such as eyes, gut and body parts such as heels, pads and gluteus from
mechanical stress; ii) conferring insulation and thermoregulation
[127]; iii) protecting the organism from lipotoxicity [128]; iv) being a
major reservoir of mesenchymal stem cells [129] and immune system
cells (e.g. macrophages and T cells) [130]; and v) functioning as an
important endocrine organ [117]. WAT undergoes massive expansion
and contraction in response to chronic alterations in energy balance,
accounting for as little as 5% of the body mass in extremely lean
athletes [131] or as much as 65% of the body mass in obese individuals
[132], corresponding to the largest tissue of the body. Moreover, in
most mammals, the WAT can completely regenerate itself following
lipectomy [133–135]. This striking degree of plasticity is unique among
the organs of adult mammals. At the cellular level, adipose tissue
expansion is driven by both hypertrophy and hyperplasia of adipocytes
[136–138]. Even in nonexpanding fat, the pool of adipocytes frequently
renews itself to compensate for adipocyte death, with approximately
10% of adipocytes renewed annually in humans and 1–5% of adipo-
cytes being replaced each day in mice [139,140]. This is thought to be
mainly accounted for by de novo adipocyte differentiation of a pool of
committed adipocyte precursors (preadipocytes) existing within the
adipose tissue.
In contrast to WAT, BAT is specialized in burning calories to
produce heat. Brown adipocytes contain multiple lipid droplets (multi-
locular), display a large number of mitochondria with high respiration
rates, and uniquely express uncoupling protein 1 (UCP1) - a trans-
membrane protein that dissipates heat by uncoupling the respiratory
chain and allowing for substrate oxidation with low ATP production
rate [141–146]. BAT is highly vascularized and innervated [147]. This
innervation is important to the activation of a thermogenic program
that involves catecholamine signaling, nutrient mobilization and
activation of UCP1 by FFA [148]. In rodents, BAT concentrates mainly
in an interscapular depot, but can also be found in smaller fat pads in
other anatomical regions (such as perirenal and perivascular) or within
the skeletal muscle [146]. In humans, the existence of BAT was
described for the first time in 1902 by Shinkishi Hatai [149]. The
BAT described by Hatai was located under the sternocleidomastoid and
trapezius muscles and ran laterally and in parallel to the neck (Hatai,
1902). Later on, Juliet Heaton (1972) observed the presence of BAT in
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adult humans – “it is localized in the neck, along the spinal cord,
particularly in the para-aortic area, around the heart and infradiaph-
ragmatic depots in the perirenal area”[150]. She added that during the
first decade of life there is a wide distribution of active brown fat, but
this distribution disappears gradually with age. More recently, dis-
coveries showed that adult humans maintain an active pool of brown
adipocytes located around the supra-clavicular and cervical regions of
the body [151–160].
In both rodents and humans, adipocytes with brown characteristics
can also be found within WAT (particularly in sWAT) in response to
cold exposure, beta-adrenergic stimulation, exercise or caloric restric-
tion [146,158,161–164]. Like classic (or preformed) brown adipocytes,
these cells express UCP1, exhibit multilocular lipid droplets, and
produce large amounts of heat. Due to their inducible/recruitable
characteristics and their distinct developmental origin, these adipo-
cytes are often distinguished from the other types by the name of
inducible brown, brite (brown-in-white) or beige adipocytes.
The expression of UCP1 confers to brown and beige adipocytes the
unique capacity of dissipating more heat per gram of tissue than any
other cell in the body of a mammal [165–167], contributing to nearly
50% of the total oxygen consumption of a rat in the cold [168]. Ucp1
knockout mice develop obesity even under thermoneutrality due to
impairment of diet-induced thermogenesis [169]. In humans, studies
demonstrate that BAT-mediated cold activation increases energy
expenditure by up to 28% [170–173] and diet-induced thermogenesis
by 32% in young men [174]. It is also estimated that 50–100 mL of
BAT can increase energy expenditure by 150–300 kcal a day in cold
exposed healthy men [173]. Interestingly, the amount of functional
BAT or beige fat in adult humans and rodents is inversely correlated
with adiposity and age, which raises the possibility of promoting brown
adipogenesis to prolong metabolic healthspan and prevent obesity
[146,157,175–178].
UCP1–expressing adipocytes are also a “metabolic sink” for glucose
and triglycerides, as they are responsible for clearing up to 75% and
50% of the total glucose and triglycerides from circulation in cold
exposed mice [179,180]. Although still debatable, recent studies have
demonstrated that BAT activation in humans can contribute to the
clearance of glucose from the circulation [reviewed by [179]]. These
findings point to the potential of activating and/or recruiting brown or
beige adipocytes to induce energy expenditure and improve glucose
control. In practice, this could be achieved by the recruitment of newly
formed UCP1-expressing cells from adipogenic precursor cells or by
the induction of UCP1 expression in differentiated adipocytes. Both
mechanisms have been shown to effectively induce energy expenditure
and limit weight gain in mice when stimulated by pharmacological or
genetic interventions [181,182].
The functional identity of UCP1-expressing adipocytes is deter-
mined by both cell autonomous and cell non-autonomous mechanisms.
Transcriptional regulators such as PRDM16 (PR domain containing
16), PGC1α (Peroxisome proliferator-activated receptor gamma coac-
tivator 1-alpha), and C/EBPβ (CCAAT/enhancer-binding protein beta)
[183–186] are among the players required for the commitment and
differentiation of brown or beige cells. Cold exposure, exercise, cancer
cachexia, caloric restriction, or a rich social and physical environment
are among the environmental cues that promote brown/beige fat
activation and/or recruitment in mammals [161,162,184,187,188].
These conditions affect the expression of key transcriptional and
post-transcriptional regulators in preadipocytes or in differentiated
adipocytes, pushing these cells towards the activation of a brown-like
gene expression signature, which in turn leads to UCP1 expression,
mitochondrial biogenesis and energy dissipation. Some of these
external cues are determined by endocrine function, i.e. by hormones
or metabolites that are secreted in the circulation or locally, such as
catecholamines, fibroblast growth factors (FGF), bone morphogenetic
proteins (BMP), growth/differentiation factor 5 (GDF5), natriuretic
peptides, prostaglandins, vascular endothelial growth factor (VEGF),
and β-aminoisobutyric acid [reviewed by [179]]. For instance, the
thermogenic effects of exercise have been linked to the recruitment of
beige adipocytes by circulating molecules such as irisin, IL-6 and
meteorin-like [161,189,190]. Some tumors also secrete molecules like
IL-6 and PTHrP to induce beige adipocyte recruitment in WAT, a
phenomenon that leads to cancer cachexia [187,191]. Interestingly, the
appearance of beige adipocytes in WAT after cold exposure or exercise
requires the involvement of eosinophils and M2 macrophages, placing
the immune system as a key regulator of adipocyte fate [189,192].
The developmental origin of precursor cells also plays a role in
adipocyte functional determination [193–196]. In a groundbreaking
study, Seale et al., 2008 demonstrated that brown but not white
adipocytes arise from progenitor cells expressing Myf5 (myogenic
factor 5), sharing a common precursor lineage with myoblasts [197].
Moreover, they found that the transcription regulator PRDM16 is
essential for brown fat fate determination [197]. Indeed, different fat
depots have different precursors with intrinsic characteristics that
confer phenotypical differences to the adipose tissue [196,198,199],
but these characteristics are not sufficient to ultimately determine the
phenotype of the adipocyte upon differentiation. For example, white
adipocytes located at the dorsal-anterior region in mice also derive
from Myf5 progenitors [200,201]. Differences in adipocyte character-
istics can even be determined after differentiation. Rosenwald et al.,
2013 showed that white adipocytes within sWAT have a bi-potential to
be white or brown depending on the stimulus [126]. They also revealed
that beige adipocytes rapidly acquire white-like characteristics upon
removal of external stimuli without passing through an intermediate
precursor stage [126,202]. Understanding the mechanisms underlying
the functional heterogeneity of adipocytes and fat depots has been a
major goal of the field. Only by seeking this goal we will be able to
manipulate fat cells to help people with metabolic diseases to better
handle substrates and adjust their energy balance. Small non-coding
RNAs (sncRNAs) appear as essential molecules in this context and
therefore will be explored in details during this Review.
4. Small non-coding RNAs (sncRNAs)
The central dogma of molecular biology postulates that the genetic
information contained in the DNA is transcribed into messenger
molecules (e.g. messenger RNA - mRNA), which are in turn translated
into proteins that exert function [203,204]. This affirmation is not
untruthful but is rather incomplete. The discovery of an abundant class
of regulatory non-coding RNAs (ncRNAs) opened too many exceptions
to the dogma and revolutionized molecular biology as we know it
[205,206].
SncRNAs is a sub-class of ncRNAs with maximum length of 199-nt
and is further classified into at least 25 different types of molecules
based on length, structure, precursor, processing machinery, organism
expression, tissue expression and function [207] (Table 1). Most
sncRNAs are involved in fine tuning gene expression by interacting
with target mRNA or with proteins involved in mRNA translation
[208,209], and in some cases, they can interact with the chromatin to
cause genomic rearrangements or epigenetic modifications [210–214].
Despite the wide variety of sncRNAs and their function in the cell,
the literature has largely focused on the role of sncRNAs in RNA
interference (RNAi) - a process where sncRNA molecules inhibit gene
expression and/or translation by targeting mRNAs [215]. The process
of RNA-mediated silencing was first observed in experiments using
plants and viruses, where scientists found transcriptional inhibition by
exogenous antisense RNA [216–218]. Later on, elegant experiments
performed by Craig Mello, Andrew Fire and colleagues identified the
mechanisms underlying such phenomenon [219]. In brief, they found
that injection of C. elegans with double-stranded RNA (dsRNA)
efficiently silences endogenous genes that share complementary se-
quences with the exogenous RNA. Remarkably, the effect was found to
be transgenerational and not to occur when single stranded mRNA or
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antisense RNA is administered. The biological and technological
implications of these findings were immediately noticed and studies
were designed to understand the role of ncRNAs in essentially all the
tree of life. This was further motivated by the identification of
endogenous ncRNAs with potential regulatory roles. In 1993, studies
from the Ruvkun and the Ambros labs independently identified lin-4 as
a tiny ncRNA that controlled developmental timing in C. elegans
[220,221]. In a series of genetic and biochemical experiments, they
found that the locus of lin-4 coded for two small RNAs of approxi-
mately 22 and 61 nt, in which the sequence of the former was
contained in the latter. They also identified in these molecules
complementary sequences to the 3′-untranslated region (3’-UTR) of
the lin-14 mRNA – a gene that was known to genetically interact with
lin-4 [220,221]. The authors predicted that lin-4 could regulate lin-14
translation through RNA-RNA interaction and anticipated a mechan-
ism that would be characterized only several years later. Pushed by the
discovery of RNAi as an endogenous and evolutionarily conserved
biological process in the late 1990s, Ambros, Ruvkun and many others
went on to identify similar tiny ncRNAs in different species across
kingdoms and named them microRNAs (miRNAs) [220–224].
As of today, many other endogenous sncRNAs with silencing
activity have been identified and functionally characterized.
Didactically, the most studied ones compose three sub-classes: i)
piwi-RNAs (piRNA); ii) endogenous small interference RNAs (endo-
siRNAs) and iii) miRNAs. The first group is found in both invertebrates
and vertebrates, where they are essential for fertility [225–229]. They
are considered the longest sncRNA of the three classes, ranging from
25 to 33 nt in length [230]. PiRNAs can be found in the nucleus, where
they regulate epigenetic and post-transcriptional gene silencing of
retrotransposons [231,232], or in the cytoplasm, where they target
the 3’-UTR of target mRNAs to promote decay [233]. Despite elegant
studies in the topic [234,235], the mechanism of piRNA biogenesis in
most species is not fully understood. What is clear is that this
mechanism differs from the canonical processing of siRNAs and
miRNAs since it is DICER-independent (see more below) [236].
Instead, piRNAs interact with PIWI-clade proteins, which determine
their processing and mediate gene silencing [230,236].
Endo-siRNAs are found mainly in plants and lower animals that do
not have antibody or cell-mediated immunity (e.g. fungi, insects and
nematodes), where their main function is to serve as a defense against
viral infections [237,238]. Nonetheless, endo-siRNAs can also regulate
gene expression in mouse oocytes or stem cells [239,240]. They derive
from long dsRNA molecules such as intergenic repetitive elements,
pseudogenes, and endo-siRNA clusters [241]. Endo-siRNA processing
varies slightly across different species, but in all of them the long
dsRNA is processed by the type III endoribonuclease DICER to
generate 20–25 bp siRNA duplexes that are unwinded and loaded into
the RNA-induced silencing complex (RISC) where proteins of the
Argonaute family (AGO) are located [241]. The RISC complex loaded
with the siRNA is guided to its target mRNA by perfect sequence
complementarity, therefore directing the mRNA to degradation [241].
MiRNAs are the most studied class of sncRNAs. They differ in many
aspects from piRNAs and endo-siRNAs, like in their tendency to be
conserved in sequence across the evolutionary spectrum and their
function as essential regulatory molecules in most cell types [207,242].
They are similar in length and share some components of the
processing/silencing machinery with siRNAs, particularly at the dicing
step and downstream, but also differ in many ways [207,242]. There
are nuances when comparing the miRNA processing pathway across
organisms, although in general this process is highly conserved. To
avoid confusion, we will describe here the mammalian pathway unless
stated otherwise (Fig. 1).
MiRNA primary transcripts (pri-miRNAs) are classified as inter-
genic or intronic according to the genomic location where they are
expressed. Intergenic pri-miRNAs are transcribed as independent
transcription units, whereas intronic pri-miRNAs are processed from
introns of their host transcripts [243,244]. In general, pri-miRNAs are
transcribed by the RNA polymerase II and are 5’-capped and 3’-
polyadenylated [245]. In some cases, like for the cluster of miRNAs
expressed in the human chromosome 19, a common pri-miRNA
Table 1
Summary of types of sncRNAs with potential or described function across the animal kingdom. (?), function not well defined.
Name Abbrev Class Length (nt) Function Ref
C/D snoRNA-derived RNA snRNA C/D sdRNA snRNA 17–19, 27 Post-transcriptional gene repression, processing of pre-rRNA [352,353]
Centromere repeat-associated sRNA crasiRNA chRNA 34–42 Heterochromatin formation [354,207]
Double-strand break induced sRNA diRNA DSB 21 DNA double-strand break repair [355–357]
Endogenous small interfering RNA endo-siRNA siRNA 21–26 Inhibition of retrotransposition, pos-transcriptional gene
repression
[358,359]
Exogeneous small interfering RNA exo-siRNA siRNA 21 Gene silencing, anti-viral [360,361]
H/ACA snoRNA-derived RNA snRNA H/ACA sdRNA snRNA 20–24 Post-transcriptional gene repression, alternative splicing [362–364]
microRNA miRNA miRNA 19–22 Post-transcriptional gene repression [221,365]
miRNA-offset RNAs moRNA miRNA 19–22 Post-transcriptional gene repression [367,368]
Promoter-associated small RNAs PASRs 18–200 Transcriptional regulation [369,370]
Piwi interacting RNA or repeat-
associated siRNA
piRNA or
rasiRNA
piRNA 25–33 Germline post-transcriptional gene repression, transposon
regulation, chromatin modification
[230,242,371]
Pyknon Pyknon miRNA/
siRNA
16–22 Post-transcriptional gene repression [372]
Small nuclear RNA or small Cajal-
body RNA
snRNA or
scaRNA
128 Pseudouridylation of U2 spliceosomal RNA (?) [374,375]
Splice site-associated small RNA spliRNA CAsRNA 17–18 Involved in regulating epigenomic modifications and
transcription (?)
[376]
Stem-bulge RNA sbRNA Y RNA 67–133 RNA quality control, chromosomal replication [377,378]
Small NF90-associated RNA SNAR Remain to be established [379,380]
Small vault RNA svRNA vRNA 22–37 Post-transcriptional gene regulation [381,382]
Telomere-specific sRNA tel-sRNA chrRNA 24 Epigenetic regulation [385]
Transcription initiation sRNA tiRNA CAsRNA 18 Transcriptional regulation [369,386]
tRNA derived halves tRH tDR 30–35 Post-transcriptional gene repression [387,388]
tRNA-derived fragments tRF tDR 20 Post-transcriptional gene repression, translational repression [389,390]
Transcriptional start-site-miRNA TSS-miRNA miRNA 20–90 Post-transcriptional gene regulation [369,391]
Unusually small RNA usRNA miRNA 15–17 Post-transcriptional gene regulation [392]
Y RNA-derived small RNAs Y RNA yDR Y RNA 24–25, 30 Ro-RNA particle to control RNA quality (?) and chromosomal
replication
[393,394]
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element is transcribed by RNA polymerase class III [246]. Pri-miRNAs
are characterized by a hairpin structure that is recognized and
processed by the microprocessing complex in the nucleus. This
complex contains DROSHA, a type III endoribonuclease that cleaves
the two strands of the hairpin at the stem approximately 22 bp away
from the terminal loop, and DiGeorge syndrome critical region protein
8 (DGCR8), a dsRNA‐binding protein that ensures efficient and
accurate processing by DROSHA [245]. This step gives rise to pre-
miRNAs, which are exported to the cytoplasm by exportin proteins
(e.g. XPO5 or Exportin-5) - a class of RanGTP-dependent dsRNA-
binding proteins [247,248].
In the cytoplasm, DICER processes the pre-miRNA at the loop to
generate miRNA duplexes of approximately 22 bp with two base
overhang on the 3’end [249,250]. To do so accurately, DICER interacts
with the HIV-1 TAR RNA binding protein (TRBP) and the Protein
ACTivator of the interferon-induced protein kinase (PACT) [251]. The
miRNA duplex is then unwinded and loaded into the RISC, where one
of the strands binds to the target mRNA (the guide strand) and mediate
gene silencing. The other strand is called passenger (or miRNA*) and is
often degraded, although some miRNAs* are capable of down-regulat-
ing different [252] or the same gene as the guide miRNA strand [253].
What determines strand preference and whether a strand will be
functionally active or be degraded is still a matter of study, but
evidence demonstrates that the thermodynamic characteristic of the
duplex and the position of the stem-loop in the pre-miRNA play a role
in this process [250,254–256]. Moreover, differences in the precursor
transcript structure (e.g. mismatches, bulges, symmetrical and asym-
metrical internal loops) determine the length diversity among miRNAs,
often called isomiRs [257–259].
Once loaded in the RISC, the miRNA recognizes the target mRNA
DICER
TRBP
PACT
RISC
AGO2
RISC
Inhibit protein
translaon
Induce 
mRNA destabilizaon
pri-miRNA pre-miRNA
RNA Pol II
passenger 
strand
miR/miR* 
duplex
AGO2
DG
CR
8
Micro-processor
complex
Fig. 1. The miRNA processing pathway. miRNA genes are transcribed by RNA polymerase II (RNA Pol II) or III into primary miRNAs (pri-miRNA). In the nucleus, the pri-miRNA is
cleaved by the microprocessor complex, comprised by the RNase III enzyme DROSHA and its partner DGCR8. This step will originate a precursor hairpin (pre-miRNA), which is
exported to the cytoplasm by Exportin-5 (XPO5). In the cytoplasm, DICER and its partners TRBP and PACT cleaves the pre-miRNA hairpin into mature miRNA (19–22 nt). The mature
miRNA will be incorporated with Argonaute 2 (AGO2) into the RNA-induced silencing complex (RISC) and will guide the RISC to silence the target mRNA by destabilizing it and/or
inhibiting its translation.
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using 6–8 complementary nucleotides (the seed region) at its 5'-end,
leading to translation inhibition and in some cases mRNA destabiliza-
tion [260]. Recently though, Broughton et al. observed that sequences
away from the seed are necessary for proper miRNA-target interaction
in C. elegans [261]. Due to the short length of the seed and imperfect
targeting mechanism, one miRNA can fine tune the expression of
hundreds of targets, while one target can be regulated by multiple
miRNAs in a combinatorial manner [262]. Thus, miRNAs take part in
complex gene network regulation, where different members of the
same network can be commonly targeted by one or more miRNAs
[263–265]. Thousands of miRNAs have been identified in humans
[262], some ubiquitously expressed and some enriched in a cell- or
time-enriched fashion [266–268]. Altogether, miRNA-mediated silen-
cing constitutes one of the most important mechanisms of gene
expression regulation of animals [269]. It is predicted that about
30% of the human mRNA is targeted by miRNAs [262]. Not surpris-
ingly, miRNAs are involved in essentially all biological processes and
dysregulation of miRNA expression is linked to a wide variety of
human diseases [270]. At the cellular level, miRNAs appear to confer
cell robustness in response to different environmental stimuli
[271,272]. Thus, miRNA dysregulation impairs cell fate decisions
[273,274], affects metabolic processes [275], and increases stress
sensitivity [271]. In adult tissues, this often results in dysfunction
and disease [276,277].
5. sncRNAs in the adipose tissue
The adipose tissue expresses a wide variety of sncRNAs with
relatively high abundance. In a mouse differentiated adipocyte cell
line, 68% of the sncRNA pool consist of miRNAs (our unpublished
data). Given the enrichment of miRNAs in adipocytes and since the
vast majority of the data on sncRNAs in adipose tissue refers to these
molecules, they will be the focus of this Review. Nevertheless, we will
discuss the potential role of other sncRNA species later on in topic 7.
When over 600 miRNAs were measured in mouse inguinal sWAT
using RT-qPCR, 265 were detected with relative abundance [271].
Each one of these individual miRNAs is expected to exhibit its own
mode of regulation that can be impacted by disease or metabolic
alterations, as we will give examples in this Review. At the genomic
level, the miRNA genes can undergo epigenetic modifications resulting
in aberrant pri-miRNA expression through DNA methylation or
histone modification [278]. Transcription factors can also influence
pri-miRNA expression [279], and this form of regulation helps setting
tissue specificity and pattern expression during development. For
example, the transcription factor p53 stimulates pri-miR-34 expression
by directly binding to its promoter region [280], while ERα inhibits pri-
miR-221 serving as a transcriptional repressor [281]. Furthermore,
there are critical nodes of regulation that affect the expression of a
broader range of miRNAs and can have a wider impact. One such node
is the miRNA processing pathway.
We and others have demonstrated that the expression of compo-
nents of the miRNA processing pathway in adipose tissue is highly
susceptible to regulation, particularly at the level of DICER (dicing
step) [178,271]. We found that aging leads to down-regulation of
approximately 50% of all miRNAs expressed in sWAT of mice – a
phenomenon that is linked to a parallel down-regulation of Dicer in
adipocytes and preadipocytes, but not in other adipose tissue cells or
non-adipose tissues [271]. General down-regulation of miRNAs and
decreased DICER1 levels with aging are also found in human pre-
adipocytes [271]. In humans, DICER1 levels are lower in subcutaneous
fat depots of patients with partial lipodystrophy when compared to
healthy individuals, and this is associated with “whitening” and
dysfunction of the tissue [39,271]. Moreover, obesity and progeria
have a global impact on miRNA expression in mouse BAT [178]. In
conditions of diet- and genetically-induced obesity, these changes are
associated with down-regulation of Dicer [178]. Importantly, a modest
reduction in BAT Dicer levels (25%) results in down-regulation of more
than 75% of the most highly expressed miRNAs in the tissue [178],
indicating that Dicer is a rate-limiting enzyme in miRNA processing in
brown fat. These results evidence an important aspect of the miRNA
processing pathway in the adipose tissue – the fact that minor
expression changes in its components exert a major impact on
miRNA expression. Nonetheless, not all the miRNAs are sensitive to
this type of regulation and some are in one fat depot but not in others.
This is consistent with the notion that each miRNA has its own mode of
regulation, and context may determine whether changes in the miRNA
processing machinery will affect the expression of the mature miRNA.
6. Adipose tissue miRNAs and adipose tissue function
Evidence that miRNAs are important for adipose tissue function
came from studies using gain- or loss-of-function approaches to
manipulate components of the miRNA processing machinery or
individual miRNAs. Initial studies using tissue culture indicated a
necessary role for miRNAs in preadipocyte differentiation and adipo-
cyte fate determination [282–284]. The in vivo experiments came to
support this notion and also demonstrate that adipocyte miRNAs play
an important role in organismal homeostasis. For example, adipocyte-
specific Dicer knockout mice (AdicerKO) exhibit a phenotype that
resembles humans with partial lipodystrophy, i.e. atrophy of WAT,
hypertrophy and “whitening” of BAT, insulin resistance, dyslipidemia,
impaired resistance to oxidative stress and premature aging [274,285].
Furthermore, these mice are refractory to many of the beneficial effects
exerted by caloric restriction, such as improved oxidative metabolism
and increased mitochondrial biogenesis in adipocytes, reduced inflam-
mation in adipose tissue, and increased whole body insulin sensitivity
[285]. Similarly, adipocyte-specific DGCR8 knockout mice
(ADGCR8KO) show alterations in fat distribution, “whitening” of
BAT, and insulin resistance [286]. Thus, miRNA deficiency leads to
impairment of basic functions of adipocytes, such as differentiation and
fate, metabolism, and signaling. This impacts on adipose tissue
characteristics, cellularity and size, which in turn leads to abnormal
fat accumulation and results in the metabolic syndrome. As much as it
was found that global changes in miRNA biogenesis are important for
adipose tissue function in a rather complex manner in the context of
the metabolic syndrome (see discussion below in topic 8), the
contribution of individual miRNAs to the phenotype is undeniable.
We will therefore describe the mode of regulation and function of
specific miRNAs in a discrete manner, as they were first identified.
Some examples will be provided in the text below, but a comprehensive
compilation of miRNAs with reported function in the adipose tissue is
presented in Table 2. Didactically, we divided miRNAs in three topics,
according to their function: a) adipogenesis, b) metabolism and c)
signaling. We believe that these three cellular processes are hallmarks
of a properly functional adipose tissue, and defects in any one of these
processes can lead to metabolic diseases (Fig. 2).
6.1. miRNAs involved in adipogenesis
The adipogenic process is very tightly regulated [139,287]. The total
number of adipocytes is determined in the period from childhood to
adolescence and is maintained constant during adulthood, in lean and
obese individuals [139,287]. Nonetheless, in 8.3 years, approximately
50% of the pool of adipocytes of an adult human is renewed [139,287].
Adipocyte turnover is sustained by adipose-derived stem cells (ADSCs)
and preadipocytes [288]. ADSCs are similar to stem cells derived from
the bone marrow, i.e. they are both multipotent and can differentiate
into a variety of cell types, such as osteoblasts, chondrocytes, myocytes,
and adipocytes (white or brown) [288–290]. Preadipocytes are one
step down in the commitment path to the adipogenic lineage, and given
their high proliferation rate are usually the main source of newly
formed adipocytes [291].
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The pro-adipogenic transcription factors peroxisome proliferator-
activated receptor-γ (PPARγ) and CCAAT-enhancer-binding proteins
(C/EBPs), as well as the anti-adipogenic signaling cascade triggered by
Wnt, BMPs, transforming growth factor beta (TGFβ) or hedgehog
participate in the regulation of ADSC commitment into the adipose
linage and control adipocyte differentiation [292]. Differentiation and
maturation of healthy, functional adipocytes involve the activation of
intricate molecular pathways organized in three subsequent steps: i)
commitment, the stage where ADSCs differentiate into adipocyte
precursor cells (including preadipocytes); ii) mitotic clonal expansion,
which in tissue culture is triggered by confluence and growth arrest;
and iii) terminal differentiation [293,294]. During the first step of
commitment, ADSCs can give rise to two different precursors: a) one
that will differentiate into white or beige adipocytes and another that
will differentiate into brown adipocytes or myocytes [127]. All these
steps have been shown to be regulated by miRNAs.
For instance, a study by Hung et al. showed that incubation of a
mesenchymal stem cell line (C3H10T1/2) with adipocyte differentia-
tion medium up-regulates miR-204/211 and down-regulates Runt-
related transcription factor 2 (Runx2), an osteogenic transcriptional
factor stimulated by Wnt and the BMP pathways. Additionally, over-
expression of miR-204 in C3H10T1/2 suppresses Runx2 expression
and stimulates the commitment of these cells to the adipose lineage
[295]. In a parallel study, Zaragosi et al. showed that the miR-30 family
is highly up-regulated during adipogenesis of ADSCs and revealed that
miR-30a and miR-30d can also target Runx2, which in turn favors
adipocyte differentiation [296]. Similarly, miR-17-5p and miR-106a
promote adipogenesis and inhibit osteogenesis of ADSCs by targeting
the pro-osteogenic protein BMP2 [297]. Interestingly, adipose tissue
miR-17-5p expression is inversely correlated with markers of hyper-
glycemia and insulin resistance in humans [298,299].
MiRNAs can also silence myogenic genes to favor adipogenesis. The
miR-193b-365 cluster is highly expressed in BAT, where it induces
common myogenic/adipogenic precursors to commit and differentiate
into brown adipocytes [300]. The miR-193b-365 cluster is induced by
PRDM16 [300], a transcriptional coregulator that is necessary for
brown/beige adipocyte differentiation [301]. Once up-regulated, miR-
193b targets the pro-myogenic factors Cdon and Igfbp5, inhibiting
myogenesis and promoting adipogenesis [300]. More recently, miR-
193b (and the seed-related miR-328) was shown to target the β-
secretase Bace1 to promote brown adipogenesis [178]. Importantly,
miR-193b is down-regulated in subcutaneous adipose tissue of obese
individuals [299,302,303].
In addition to inhibiting osteogenic or myogenic commitment to
favor adipocyte differentiation, miRNAs can directly silence inhibitors
of adipogenesis. For example, miR-21 expression is up-regulated
during adipogenic differentiation of ADSCs, which leads to silencing
of TGFβ receptor-2, hence suppressing the adipogenic inhibition
caused by TGFβ [304]. Moreover, miRNAs can inhibit adipogenesis.
MiR-133 targets PRDM16 mRNA in muscle stem cells therefore
inhibiting commitment to the brown adipocyte lineage and allowing
myogenesis [305]. Thus, miRNAs interact with signaling pathways and
transcriptional regulators that are normally involved in developmental
control to determine commitment and differentiation of ADSCs.
Once committed, adipogenic precursor cells need to proliferate.
During cell proliferation, transition from G1 to S is regulated by the
retinoblastoma protein (Rb)/E2F pathway [306]. Cyclin kinase-depen-
dent hyperphosphorylation of Rb releases E2F to transcriptionally
activate genes involved in the S phase [306]. The transition between
these two phases of the cell cycle is extremely important and dictates
whether preadipocytes will in fact reach terminal differentiation
[307,308]. During early differentiation, after proliferation and
growth-arrest, preadipocytes need to reentry the cell cycle and undergo
approximately two rounds of divisions (i.e.mitotic clonal expansion) in
order to differentiate [307,309]. Like the other steps in adipogenesis,
miRNAs also control mitotic expansion.T
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Wang et al. demonstrated that the expression of the miR-17–92
cluster matches with the time of reentry and exit of the cell cycle. They
observed that the miR-17–92 cluster reaches its peak after one day of
the adipogenic stimulus in 3T3-L1 preadipocytes, coinciding with the
down-regulation of the retinoblastoma-like protein 2 (Rb2/p130) and
inducing reentry in the cell cycle [310]. After this, the miR-17–92
cluster is down-regulated and Rb2/p130 expression is increased,
exiting cells from the cell cycle for terminal differentiation [310]. In
contrast, miRNAs such as the members of the let-7 family (which target
the mRNA of high mobility group AT-hook2 protein HMGA2) and
miR-363 (which targets E2F3 mRNA) inhibit mitotic clonal expansion
and terminal differentiation of adipocytes [311,312].
Fat accumulation characterizes the final stage of adipogenesis. Once
the fate of the adipocyte is determined, lipids start accumulating in
response to growth factor signaling and a positive energy balance
[313–315]. Insulin and PPARγ are the main drivers of adipogenesis at
this step [316]. Among the downstream kinases activated by insulin, it
is worth mentioning the extracellular signal-regulated kinase (ERK).
Tight regulation of ERK is essential for adipocyte differentiation.
Whereas activation of ERK during precursor cell proliferation is
required for clonal expansion, activation of ERK at the final stages of
differentiation inhibits PPARγ and abrogates adipocyte differentiation
[315]. Consistent with this notion, miR-375 expression increases with
3T3-L1 adipocyte differentiation to promote lipid accumulation by
suppressing ERK1/2 phosphorylation [317].
Taken these studies together, it is safe to affirm that miRNAs play a
role in different aspects of adipocyte development. Not surprisingly,
changes in miRNAs involved with adipogenesis have been associated
with different metabolic diseases. For example, Roldan et al. observed
that miRNAs such as let-7c/d/e (which target HMGA2 and inhibit cell
proliferation), miR-23b and mir-27b (which are Wnt activators and
PPARγ and TGFβ/Smad repressors), and miR-320, miR-542-5p, miR-
140, miR-143, and miR-661 (which are associated in different manners
with adipocyte differentiation) are up-regulated in ADSCs of morbidly
obese individuals compared to lean individuals [318].
6.2. miRNAs and adipocyte metabolism
Once the adipocyte is terminally differentiated, miRNAs can
regulate basic metabolic functions of these cells, including glucose
utilization, lipid turnover, and oxidative metabolism [299]. Adipocytes
use a large portion of the available blood glucose to maintain their
function, particularly brown adipocytes [179]. Chen et al. observed that
miR-93 overexpression in adipocytes down-regulates the glucose
transporter type 4 (GLUT4) - the main insulin-sensitive glucose
transporter in these cells [319]. Importantly, miR-93 expression is
higher in adipose tissue of non-obese patients with insulin resistance,
and inversely correlates with GLUT4 levels in these individuals [319].
These changes in miRNA-mediated glucose transport capacity in
adipose tissue can therefore contribute to the pathogenesis of insulin
resistance.
Once taken up by adipocytes, glucose needs to be broken down to
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Fig. 2. Adipocyte function and examples of miRNA-mediated regulation. MiRNAs are involved in different steps of adipocyte maturation, metabolism and signaling. They regulate
adipogenesis (positively: miR-17–92, miR375 and miR-146b; negatively: let-7 and miR-363), glucose uptake (miR-93 and miR-223), lipolysis and β-oxidation (miR-145), triglyceride
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feed the mitochondria with substrates for ATP generation. Little is
known about the role of miRNAs in adipocyte glycolysis, but in other
tissues the link between glucose utilization and specific miRNAs is well
established [320,321,322]. Evidence that miRNAs control glycolysis in
adipocytes comes from our study using the AdicerKO mice [285].
Adipocytes lacking Dicer induce anaerobic glycolysis even in conditions
when oxidative metabolism is expected to be activated, i.e. during
caloric restriction [285]. This phenotype is associated with adipocyte
mitochondrial dysfunction and suggests that miRNAs are important in
adipocytes to control the engagement of adequate metabolic pathways
(i.e. oxidative vs. glycolytic) in response to changes in nutrient
availability [285].
A defective capacity of adipocyte mitochondria to oxidize substrates
has been associated with metabolic diseases [323]. The transcription
co-activators of the PGC-1 family are key regulators of mitochondrial
biogenesis, thermogenesis and glucose and fatty acid metabolism, and
are preferentially expressed in tissues with relatively high mitochon-
drial content such as the BAT [324]. The pre-miR-378 hairpin resides
within the first intron of the PCG-1β gene (Ppargc1b) and is co-
expressed with the host gene in highly oxidative tissues, including the
adipose tissue, where they counterbalance each other functions
[325,326]. Consistent with a role in fat metabolism, miR-378/378*
knockout mice are resistant to diet-induced obesity [326]. miR-378
and miR-378* target the mRNAs of carnitine O-acetyltransferase and
MED13, respectively, two important proteins involved in beta-oxida-
tion [326], and therefore inhibit oxidative metabolism.
In anabolic states, intermediates of glycolysis and the tricarboxylic
acid (TCA) cycle also serve as building blocks for lipid synthesis [327].
In adipocytes, newly synthesized fatty acids, or FFAs coming from the
circulation can be re-esterified into triglycerides for storage, in a
process called lipogenesis [327]. A rate-limiting step in lipid synthesis
is catalyzed by the stearoyl-CoA desaturase1 (SCD-1). SCD-1 mRNA is
a target of miR-125b in mammals, and overexpression of this miRNA
in adipocytes reduces triglyceride accumulation [328]. Interestingly,
miR-125b is up-regulated in mouse subcutaneous adipose tissue in
response to calorie restriction, and its overexpression in preadipocytes
confers protection from oxidative stress-induced cell death [271].
One of the main functions of adipocytes is to break down
triglycerides to mobilize FFAs and feed the organism in conditions of
negative energy balance [327]. This process, called lipolysis, is co-
ordinated by nutrient availability, hormones and, importantly, miRNAs
[327]. Lin et al. showed that miR-145 control lipolysis rate in mouse
adipocytes [329]. They studied KH‐type splicing regulatory protein
(KSRP) knockout mice [329], which lack an RNA-binding protein that
controls the synthesis of a subclass of miRNAs, including miR-145
[330,331]. KSRP-/- mice display higher lipolysis rate in epididymal fat
due to up-regulation of forkhead box protein O1 (FOXO1), comparative
gene identification-58 (CGI58) and adipose triglyceride lipase (ATGL)
[329]. Ectopic expression of miR-145 in 3T3-L1 adipocytes inhibits
Foxo1 and Cgi58mRNAs by direct targeting, and thus reduces lipolysis
[329]. Using the same mouse model, Chou et al. noted that KSRP-/-
mice are leaner due to ”browning” of the inguinal sWAT [332]. They
found that to be due to down-regulation of miR-150, which targets the
mRNAs of PRDM16 and PPARγ [332].
6.3. miRNAs involved in signaling
The adipose tissue is a major site of endocrine regulation. Molecules
secreted by the adipocytes and other adipose resident cells signal to the
organism to control metabolic function and homeostasis [107]. On the
other hand, adipocytes sense the levels of extracellular molecules that
inform them of the energy status of the organism [107]. miRNAs
control the expression of adipokines and components of signaling
pathways, therefore contributing to intercellular communication. For
example, adipose tissue miR-193b expression correlates with serum
adiponectin levels in humans [333], and as previously mentioned, is
down-regulated in obese individuals [299,302,303]. MiR-193b controls
adiponectin by targeting the mRNA of nuclear transcription factor Yα
and potentially nuclear receptor interacting protein 1, which are
negative regulators of this adipokine [333].
MiRNAs also regulate the crosstalk between adipocytes and im-
mune cells within the adipose tissue. Zhuang et al. showed that miR-
223 knockout mice are prone to high fat diet (HFD)-induced adipose
tissue inflammation and exhibit systemic insulin resistance. They
observed that macrophages from the miR-223-/- mice have a skewed
profile towards the pro-inflammatory M1 type and concluded that miR-
223 regulates macrophage polarization during obesity [334].
Interestingly, miR-223 expression in human sWAT positively corre-
lates with insulin resistance and TNF-α exposure induces the expres-
sion of this miRNA by nearly 2-fold in human differentiated subcuta-
neous adipocytes [335]. Moreover, overexpression of miR-223 blocks
insulin-stimulated glucose uptake and reduces GLUT4 expression in
these cells [335]. MiR-146b-5p and miR-155 are two other examples of
miRNAs involved with inflammation. MiR-146b-5p is decreased in
monocytes from obese patients [336] and increased in adipocytes
treated with TNF-α or IL-6 [337], while miR-155 expression levels
correlate with the number of macrophages infiltrating human sWAT
[298,299]. Consistent with a role in atherosclerosis, miR-155 loss-of-
function intensifies the inflammatory response and the uptake of lipids
by a macrophage cell line stimulated with oxidized low-density
lipoprotein (LDL) [338,339,299]. In contrast, miRNAs can correlate
with less inflammation. For instance, the levels of IL-6 in the serum of
patients with non-alcoholic steatohepatitis negatively correlate with the
adipose tissue expression of three miRNAs (namely miR-149, miR-
574-3p, and miR-132) known to target IL-6 mRNA [340].
Some miRNAs are also potent regulators of growth factor signaling.
Karolina et al. reported increased miR-144 expression in blood, liver,
muscle, and adipose tissue of type 2 diabetic patients [341]. An inverse
correlation between miR-144 and insulin receptor substrate 1 (IRS1)
expression was observed by these authors [341]. Luciferase assays
revealed that miR-144 targets the 3’-UTR of IRS1 mRNA and can
therefore regulate insulin signaling [341]. MiR-139-5p also targets
IRS1 in murine preadipocytes [342], while miR-146a-5p targets the
mRNA of insulin receptor in primary porcine adipocytes [343].
Another miRNA that affects growth factor signaling to control adipose
tissue function is miR-34a. MiR-34a is up-regulated in the subcuta-
neous fat depot of obese people [344] and inhibits beige and brown fat
formation in obese mice partially by suppressing the FGF21 signaling
pathway [345]. Inhibition of miR-34a in obese mice using systemic
administration of lentivirus-expressing antisense miR-34a increases
energy expenditure and induces thermogenic capacity in brown and
epididymal adipose tissues [345]. In contrast, Lavery et al. showed that
miR-34a knockout mice are more susceptible to weight gain under
HFD and exhibit an altered macrophage phenotype [346]. It is worth
mentioning that the strategies to knock out miR-34a were different
between the two studies, indicating a time and/or tissue dependent
function for miR-34a.
Finally, miRNAs themselves can act as signaling molecules.
MiRNAs are carried in circulation by extracellular vesicles (e.g.
exosomes) or associated with proteins (e.g. lipoproteins) [347].
Adipocytes are the main source of circulating miRNAs in mice (and
likely in humans) and these adipocyte-secreted miRNAs can be taken
up by other cells where they regulate target gene expression [348]. For
instance, adipocyte-secreted miR-99b down-regulates FGF21 in liver
[348]. Interestingly, BAT contributes more to the pool of circulating
miRNAs than WAT [348], and this secretion is potentiated by beta-
adrenergic stimulation and cold exposure [349]. Among the cold
stimulated, brown fat secreted miRNAs, circulating levels of miR-92a
negatively correlates with BAT activity both in mice and humans [349].
Interestingly, gastric bypass surgery in obese individuals affects the
expression of 168 circulating, adipocyte-derived exosomal miRNAs,
and components of the insulin signaling pathway are among the most
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enriched targets of these differentially expressed miRNAs [350].
Importantly, the expression of ten of these miRNAs correlates with
insulin resistance [350]. Hence, miRNAs can act in cell autonomous
and non-autonomous manners to regulate adipose tissue function.
7. Perspectives on the role of sncRNAs in adipose tissue
Despite the recent advances, our understanding of how sncRNAs
control adipose tissue function is still in its early stages. Publications in
PubMed containing the keywords “microRNA” and “adipose” have
grown exponentially in the last decade and sum 478 papers as of Dec
31st, 2016 – two thirds of them published in the last 3 years (data not
shown). The universe of miRNAs expressed in fat is vast, and so are
their targets and interactions. Thus, much more is expected to be
unveiled about adipose tissue miRNAs. For what is worth concerning
redox biology, almost nothing is known regarding adipose tissue
miRNAs, except for indirect links and speculation. ROS down-regulates
Dicer in murine preadipocytes and Dicer knockout preadipocytes and
young AdicerKO mice are more susceptible to oxidative stress-induced
mortality [271]. In contrast, Dicer overexpression in the C. elegans
intestine (the analog of the mammalian adipose tissue) protects worms
from oxidative stress [271]. These phenotypes are partially due to
changes in the expression of the lin-4/miR-125 family [271]. The
downstream targets of lin-4/miR-125 that confer protection from
oxidative damage are yet to be found, and so is the mechanism of
how ROS regulate Dicer expression. Indeed, the regulation of miRNA
expression in adipose tissue is a fascinating topic for future studies.
MiRNAs in adipose tissue are globally regulated by physiological
stimuli in a rather unique manner. Dicer is a rate-limiting step in
miRNA biogenesis in fat and its dynamic range of regulation is
intriguing. Why would adipocytes need to change Dicer expression so
dramatically under physiological conditions?
Perhaps the answer to this question relies on the recent discoveries
that the adipose tissue is the main source of circulating miRNAs in the
mouse and potentially humans. These findings opened up a whole new
dimension to the topic. Are adipose-derived circulating miRNAs
relevant for physiological control in mammals? It certainly does seem
so based on the most recent studies. But which miRNAs contribute to
the endocrine functions of the adipose tissue and how? These are
questions that remain to be answered.
Finally, miRNAs consist of only 68% of the total sncRNA pool of a
murine differentiated adipocyte cell line (our unpublished data). The
remaining 32% have not been characterized. Except for one match
related to a report of moRNA expression in pig adipose tissue [351]
and excluding miRNAs, there is no paper in PubMed associating any of
the sncRNAs listed in Table 1 and the adipose tissue. Unraveling this
unexplored universe is a fascinating endeavor for future studies.
8. Conclusions
SncRNAs (represented here by the well characterized and abundant
class of miRNAs) play a role in a complete range of cellular processes
that contribute to adipose tissue function, i.e. adipogenesis, metabo-
lism and signaling (Fig. 2). Impaired biogenesis of DICER-dependent
sncRNAs (e.g. miRNAs, siRNAs) in adipocytes leads to alterations in
these processes and results in features of the metabolic syndrome.
DICER is a rate limiting protein in the miRNA biogenesis pathway in
adipocytes, at least for the majority of the miRNAs expressed in these
cells. Given the importance of miRNAs in adipose tissue, DICER up-
regulation may represent a key mechanism to accelerate sncRNA
production in conditions when these molecules are necessary (as the
ones reviewed here). DICER up-regulation may not necessarily in-
crease sncRNA expression, as each sncRNA has its own mode of
regulation, but it will allow miRNAs to be expressed rapidly. This will
confer a more robust (less noisy) response to stimuli that control, for
instance, cell fate, substrate utilization and intercellular communica-
tion. More studies are necessary to determine all the pieces in this
complex puzzle, and more importantly, to find strategies to target this
pathway to minimize the suffering of patients with metabolic diseases.
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